Anti-Scl-70 Antibodies

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 792 Experts worldwide ranked by ideXlab platform

Aki Hietaharju - One of the best experts on this subject based on the ideXlab platform.

X Bossuyt - One of the best experts on this subject based on the ideXlab platform.

  • Anti-PM/Scl-100 and anti-RNA-polymerase III Antibodies in scleroderma
    Clinica Chimica Acta, 2010
    Co-Authors: L Maes, D Blockmans, P Verschueren, R Westhovens, K Op De Beéck, P Vermeersch, K Van Den Bergh, R W Burlingame, M Mahler, X Bossuyt
    Abstract:

    Abstract Background Systemic sclerosis (SSc) is a rare autoimmune disease characterized by the presence of various autoAntibodies, including anti-centromere, anti-topoisomerase (Scl-70), anti-PM/Scl-100, and anti-RNA-polymerase III (RNA Pol-III) Antibodies. Recently, new ELISA based immunoassays have become available for the detection of anti-PM/Scl and anti-RNA Pol-lII Antibodies. Objective We studied the prevalence and clinical association of anti-PM/Scl-100 (PM1-Alpha) and anti-RNA Pol-III Antibodies. Methods Antibodies to PM1-Alpha and RNA Pol-III were measured by ELISA (DR. Fooke Laboratories and Inova Diagnostics, respectively) in 242 patients with various connective tissue diseases (CTD) (including 70 SSc patients) and in 36 non-CTD controls. Results Low levels of PM1-Alpha Antibodies were found in various CTDs, whereas high levels were exclusively found in SSc, dermatomyositis and polymyositis, albeit at low frequency (4.7%). Anti-RNA Pol-III Antibodies were found in 7% of SSc and in 1% of non-CTD and CTD controls. Anti-centromere and Anti-Scl-70 Antibodies were found in 37% and 21% of SSc patients, respectively. Anti-centromere Antibodies were associated with limited cutaneous SSc and Anti-Scl-70 Antibodies with diffuse cutaneous SSc and interstitial lung disease. Because of the low number of samples positive for anti-PM/Scl-100 or RNA Pol-III Antibodies, no clinical feature was statistically correlated with the presence of either reactivity, but taken together the presence of either antibody was correlated with interstitial lung disease. Anti-PM1-Alpha and anti-RNA Pol-III Antibodies were mutually exclusive with Anti-Scl-70 Antibodies. Conclusions At high levels, anti-PM/Scl-100 Antibodies were associated with SSc, PM, and DM, albeit at low frequency. Anti-RNA Pol-III Antibodies were associated with SSc (in 7%) with high specificity.

  • Anti-PM/Scl-100 and anti-RNA-polymerase III Antibodies in scleroderma.
    Clinica chimica acta; international journal of clinical chemistry, 2010
    Co-Authors: L Maes, D Blockmans, P Verschueren, R Westhovens, K Op De Beéck, P Vermeersch, K Van Den Bergh, R W Burlingame, M Mahler, X Bossuyt
    Abstract:

    Systemic sclerosis (SSc) is a rare autoimmune disease characterized by the presence of various autoAntibodies, including anti-centromere, anti-topoisomerase (Scl-70), anti-PM/Scl-100, and anti-RNA-polymerase III (RNA Pol-III) Antibodies. Recently, new ELISA based immunoassays have become available for the detection of anti-PM/Scl and anti-RNA Pol-lII Antibodies. We studied the prevalence and clinical association of anti-PM/Scl-100 (PM1-Alpha) and anti-RNA Pol-III Antibodies. Antibodies to PM1-Alpha and RNA Pol-III were measured by ELISA (DR. Fooke Laboratories and Inova Diagnostics, respectively) in 242 patients with various connective tissue diseases (CTD) (including 70 SSc patients) and in 36 non-CTD controls. Low levels of PM1-Alpha Antibodies were found in various CTDs, whereas high levels were exclusively found in SSc, dermatomyositis and polymyositis, albeit at low frequency (4.7%). Anti-RNA Pol-III Antibodies were found in 7% of SSc and in 1% of non-CTD and CTD controls. Anti-centromere and Anti-Scl-70 Antibodies were found in 37% and 21% of SSc patients, respectively. Anti-centromere Antibodies were associated with limited cutaneous SSc and Anti-Scl-70 Antibodies with diffuse cutaneous SSc and interstitial lung disease. Because of the low number of samples positive for anti-PM/Scl-100 or RNA Pol-III Antibodies, no clinical feature was statistically correlated with the presence of either reactivity, but taken together the presence of either antibody was correlated with interstitial lung disease. Anti-PM1-Alpha and anti-RNA Pol-III Antibodies were mutually exclusive with Anti-Scl-70 Antibodies. At high levels, anti-PM/Scl-100 Antibodies were associated with SSc, PM, and DM, albeit at low frequency. Anti-RNA Pol-III Antibodies were associated with SSc (in 7%) with high specificity. Copyright 2010 Elsevier B.V. All rights reserved.

  • Evaluation of a Dot-Blot Method for Identification of Antibodies against Extractable Nuclear Antigens and Anti-Cytoplasmic Antibodies
    Clinical Chemistry, 1999
    Co-Authors: Alex Mewis, Godelieve Mariën, Norbert Blanckaert, X Bossuyt
    Abstract:

    Antibodies against extractable nuclear antigens (ENAs) are useful diagnostic markers for various autoimmune diseases. Anti-SSA and anti-SSB Antibodies are found in Sjogren Syndrome (SS), anti-Sm Antibodies are found in systemic lupus erythematosus (SLE), anti-RNP Antibodies are found in mixed connective tissue disease (MCTD), and Anti-Scl-70 Antibodies are found in scleroderma. Antibodies against cytoplasmic Jo-1 and M2 are helpful markers for the diagnosis of, respectively, polymyositis and primary biliary cirrhosis. The Antibodies can be identified by either counter immunoelectrophoresis (CIE) or immunoblotting. These techniques, however, are time-consuming, technically demanding, and do not provide for fast turnaround times. Over the last few years, alternative …

Marius Teodorescu - One of the best experts on this subject based on the ideXlab platform.

  • Anti–topoisomerase I (Anti–Scl‐70) Antibodies in patients with systemic lupus erythematosus
    Arthritis & Rheumatism, 2001
    Co-Authors: Hélène A. Gussin, Georghe P. Ignat, John Varga, Marius Teodorescu
    Abstract:

    Objective To investigate the presence and clinical significance of anti–Scl-70 Antibodies in patients with systemic lupus erythematosus (SLE). Methods Levels of Antibodies against Scl-70 were determined by a commercial clinical enzyme-linked immunosorbent assay (ELISA) during routine evaluation. Results were verified by an additional ELISA with a characterized bovine Scl-70, by ELISA with a recombinant human topoisomerase I, by Western blot, and by double diffusion in agar gel. Disease activity was estimated retrospectively by the Systemic Lupus Activity Measure (SLAM). Results Of 128 consecutive SLE patients, 25% were positive for anti–Scl-70 antibody; this antibody activity was cognate in nature. No SLE patient could be classified as also having systemic sclerosis. The levels of anti–Scl-70 were significantly correlated with the SLAM score for the entire cohort (r = 0.563, P < 0.001) and for 7 individual patients with multiple longitudinal measurements (r = 0.755–0.951, P < 0.001; n = 6) (r = 0.378, P < 0.05; n = 1). A significant correlation was also found between the levels of anti–Scl-70 and anti–double-stranded DNA Antibodies (r = 0.558, P < 0.001). Patients with anti–Scl-70 had significantly higher risk of pulmonary hypertension (P < 0.01) and renal involvement (P < 0.001) than patients without this antibody. Conclusion Anti–Scl-70 antibody is present in a significant subset of patients with SLE. For this subset, it offers a good correlate of disease activity and suggests increased risk for pulmonary hypertension and nephritis.

  • Anti-topoisomerase I (Anti-Scl-70) Antibodies in patients with systemic lupus erythematosus.
    Arthritis and rheumatism, 2001
    Co-Authors: Hélène A. Gussin, Georghe P. Ignat, John Varga, Marius Teodorescu
    Abstract:

    Objective To investigate the presence and clinical significance of anti–Scl-70 Antibodies in patients with systemic lupus erythematosus (SLE). Methods Levels of Antibodies against Scl-70 were determined by a commercial clinical enzyme-linked immunosorbent assay (ELISA) during routine evaluation. Results were verified by an additional ELISA with a characterized bovine Scl-70, by ELISA with a recombinant human topoisomerase I, by Western blot, and by double diffusion in agar gel. Disease activity was estimated retrospectively by the Systemic Lupus Activity Measure (SLAM). Results Of 128 consecutive SLE patients, 25% were positive for anti–Scl-70 antibody; this antibody activity was cognate in nature. No SLE patient could be classified as also having systemic sclerosis. The levels of anti–Scl-70 were significantly correlated with the SLAM score for the entire cohort (r = 0.563, P < 0.001) and for 7 individual patients with multiple longitudinal measurements (r = 0.755–0.951, P < 0.001; n = 6) (r = 0.378, P < 0.05; n = 1). A significant correlation was also found between the levels of anti–Scl-70 and anti–double-stranded DNA Antibodies (r = 0.558, P < 0.001). Patients with anti–Scl-70 had significantly higher risk of pulmonary hypertension (P < 0.01) and renal involvement (P < 0.001) than patients without this antibody. Conclusion Anti–Scl-70 antibody is present in a significant subset of patients with SLE. For this subset, it offers a good correlate of disease activity and suggests increased risk for pulmonary hypertension and nephritis.

Marja Hietarinta - One of the best experts on this subject based on the ideXlab platform.

John D. Reveille - One of the best experts on this subject based on the ideXlab platform.

  • Anti-Scl-70.
    Autoimmunity, 2005
    Co-Authors: Dhiman Basu, John D. Reveille
    Abstract:

    Objective: To develop an overview focusing on the utility of Anti-Scl-70 autoantibody determinations in the rheumatic diseases. Methods: Articles from electronic literature searches were retrieved, critiqued and data were extracted and pooled on Anti-Scl-70 (topoisomerase I) in relation to history, optimal tests used for its detection, sensitivity, specificity, positive and negative likelihood ratios, indications, interpretation and pitfalls. Results: Anti-Scl 70 Antibodies are very useful in distinguishing systemic sclerosis (SSc) patients from healthy controls, from patients with other connective tissue diseases, and from unaffected family members. Among patients with SSc, Anti-Scl-70 positivity is useful in predicting those at higher risk for diffuse cutaneous involvement and interstitial fibrosis/restrictive lung disease, though the latter has not been universally observed. Of the four different techniques notably immunodiffusion, immunoblotting, immunoprecipitation and enzyme-linked immunosorbent ass...

  • The clinical relevance of autoAntibodies in scleroderma
    Arthritis Research & Therapy, 2003
    Co-Authors: Khanh T Ho, John D. Reveille
    Abstract:

    Scleroderma (systemic sclerosis) is associated with several autoAntibodies, each of which is useful in the diagnosis of affected patients and in determining their prognosis. Anti-centromere Antibodies (ACA) and Anti-Scl-70 Antibodies are very useful in distinguishing patients with systemic sclerosis (SSc) from healthy controls, from patients with other connective tissue disease, and from unaffected family members. Whereas ACA often predict a limited skin involvement and the absence of pulmonary involvement, the presence of Anti-Scl-70 Antibodies increases the risk for diffuse skin involvement and scleroderma lung disease. Anti-fibrillarin autoAntibodies (which share significant serologic overlap with anti-U3-ribonucleoprotein Antibodies) and anti-RNA-polymerase autoAntibodies occur less frequently and are also predictive of diffuse skin involvement and systemic disease. Anti-Th/To and PM-Scl, in contrast, are associated with limited skin disease, but anti-Th/To might be a marker for the development of pulmonary hypertension. Other autoAntibodies against extractable nuclear antigens have less specificity for SSc, including anti-Ro, which is a risk factor for sicca symptoms in patients with SSc, and anti-U1-ribonucleoprotein, which in high titer is seen in patients with SSc/systemic lupus erythematosus/polymyositis overlap syndromes. Limited reports of other autoAntibodies (anti-Ku, antiphospholipid) have not established them as being clinically useful in following patients with SSc.